Área de Psiquiatría, Universidad de Oviedo, Oviedo, Spain,
Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain,
Eur Addict Res. 2019;25(3):111-118. doi: 10.1159/000497317. Epub 2019 Mar 21.
Data on associations between cannabis use and psychopathology, cognition and functional impairment in schizophrenia spectrum disorders (SSD) is controversial.
To examine the effect of cannabis on psychopathology, cognition and real-world functioning in SSD patients.
Naturalistic cross-sectional study, 123 clinically stable SSD outpatients.
demographic and clinical data, psychometric evaluation: Positive and Negative Syndrome, Hamilton Depression Rating, Clinical Global Impression (CGI), Personal and Social Performance and Screen for Cognitive Impairment in Psychiatry (SCIP) scales. Patients were classified as cannabis user patients (CUP) and non cannabis user patients (NCUP) according to self-report, both lifetime and last year.
chi-square, Student t test, ANOVA (Duncan post hoc), and general linear model analysis for adjusting for antipsychotic doses.
Mean age 40.75, 66.7% male, single (66.7%), prior hospital admissions 2.75, mean length of illness 13.85 years. 53.7% were lifetime cannabis users and 8.9% last year users. Lifetime CUP had more hospitalizations (p = 0.013) at a younger age (p = 0.002), and showed better cognitive functioning globally (CGI-C: p = 0.045) and on working memory and processing speed (SCIP-2: p = 0.039; SCIP-5: p = 0.033) and worse functioning in socially useful activities (p = 0.014) than NCUP. All these differences remained after adjusting for antipsychotic doses. Last year cannabis users had worse mood (Hamilton Depression Rating Scale 9.66 vs. 5.64; p = 0.002), but this difference disappears when adjusting for antipsychotic doses.
Lifetime cannabis use is associated with better working memory and processing speed and worse real-world functioning in the area of socially useful activities in patients with schizophrenia-related disorders. Clinicians should, therefore, be aware of it to provide patient-centred care in their daily clinical practice.
关于大麻使用与精神分裂症谱系障碍(SSD)患者的精神病理学、认知和功能障碍之间的关联,数据存在争议。
研究大麻对 SSD 患者精神病理学、认知和现实世界功能的影响。
自然横断面研究,共纳入 123 例临床稳定的 SSD 门诊患者。
人口统计学和临床数据,心理评估:阳性和阴性综合征量表、汉密尔顿抑郁量表、临床总体印象量表(CGI)、个人和社会表现量表和精神科认知障碍筛查量表(SCIP)。根据患者自我报告,将其分为大麻使用者(CUP)和非大麻使用者(NCUP),包括终生和去年使用情况。
卡方检验、学生 t 检验、方差分析(Duncan 事后检验)和一般线性模型分析,用于调整抗精神病药物剂量。
平均年龄为 40.75 岁,66.7%为男性,单身(66.7%),既往住院 2.75 次,平均发病病程为 13.85 年。53.7%为终生大麻使用者,8.9%为去年使用者。终生 CUP 组患者住院次数更多(p = 0.013),发病年龄更早(p = 0.002),总体认知功能更好(CGI-C:p = 0.045),在工作记忆和处理速度方面更好(SCIP-2:p = 0.039;SCIP-5:p = 0.033),在社会有用活动方面功能更差(p = 0.014),而 NCUP 组则相反。所有这些差异在调整抗精神病药物剂量后仍然存在。去年大麻使用者的情绪更差(汉密尔顿抑郁量表评分 9.66 分 vs. 5.64 分;p = 0.002),但在调整抗精神病药物剂量后,这种差异消失。
在与精神分裂症相关障碍的患者中,终生大麻使用与更好的工作记忆和处理速度以及更差的社会有用活动领域的现实世界功能相关。因此,临床医生在日常临床实践中应注意这一点,为患者提供以患者为中心的护理。